<SEC-DOCUMENT>0001193125-12-046070.txt : 20120412
<SEC-HEADER>0001193125-12-046070.hdr.sgml : 20120412
<ACCEPTANCE-DATETIME>20120208140711
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-12-046070
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				650271219
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Correspondence</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g297036corresp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;8, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Via EDGAR Submission </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Jim B. Rosenberg </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Assistant Chief Accountant </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Division of
Corporation Finance </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities and Exchange Commission </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">100 F Street, NE </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, D.C. 20549 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Re:</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MEDNAX, Inc. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>File
No.&nbsp;001-1211 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form 10-K for the Year Ended December&nbsp;31, 2010 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Mr.&nbsp;Rosenberg: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
letter is in response to the Staff&#146;s comments, set forth in your letter received by e-mail on February&nbsp;1, 2012 (the &#147;<B>Comment Letter</B>&#148;), addressed to Vivian Lopez-Blanco as Chief Financial Officer of MEDNAX, Inc. (the
&#147;<B>Company</B>&#148;), relating to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Staff&#146;s comments, which for ease of reference are set forth below, are addressed in the order in which they are presented in the Comment Letter. In the responses below, references to
&#147;we&#148;, &#147;our&#148; and &#147;us&#148; refer to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Consolidated Financial Statements </U></I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Notes to Consolidated Financial Statements </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>2. Summary of Significant Accounting Policies </U></I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Business
Acquisitions, page 60 </U></I></B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>1.</I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In your response to our third comment, you state that you remeasure the fair value of contingent consideration at each reporting period for those acquisitions
completed on or after January&nbsp;1, 2009. Please clarify whether you remeasure the contingent consideration regardless of whether it is classified as an asset/liability or as equity. If so, please tell us how your accounting is consistent with ASC
805-30-35-1. If not, please revise your disclosure to describe how you account for the consideration differently. </I></B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our contingent consideration arrangements relate to agreements to pay additional cash amounts in future periods based on the achievement of performance goals. Accordingly, all of our contingent
consideration arrangements for acquisitions completed after January&nbsp;1, 2009 are recorded and classified as liabilities on the acquisition date and are remeasured at each reporting period in accordance with ASC 805-30-35-1. We understand that
contingent consideration classified as an asset would also be remeasured at each reporting period; however, we do not have contingent consideration assets at this time and do not anticipate entering into agreements for contingently returnable
consideration. Further, we understand that contingent consideration classified as equity is not remeasured subsequent to initial recognition, and that settlement of the equity-classified contingent consideration is recorded within equity. However,
we do not have contingent consideration classified as equity and do not anticipate entering into agreements that would require (or at our option require) settlement in shares. We will continue to evaluate contingent consideration arrangements in
accordance with ASC 805. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to your comment, we will expand our disclosure related to
contingent consideration within our business acquisitions accounting policy in future periodic reports to clarify that all contingent consideration arrangements pertain to additional amounts to be paid in cash and that such amounts are classified as
liabilities on our balance sheet as follows: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Business Acquisitions </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for business acquisitions as required by the provisions of the accounting guidance for business
combinations, which includes provisions that the Company adopted effective January&nbsp;1, 2009. The guidance retains the underlying concepts of the previous standard such that all business combinations are required to be accounted for at fair
value, but changes certain aspects of applying the acquisition method of accounting. The changes also require the Company to expense certain acquisition costs as they are incurred. In accordance with the acquisition method of accounting, any
identifiable assets acquired and any liabilities assumed are recognized and measured at their fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the
reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the
fair values; however, the period will not exceed one year from the acquisition date. Any material adjustments recognized during the measurement period will be reflected retrospectively in the consolidated financial statements of the subsequent
period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>In connection with certain acquisitions, the Company enters into agreements to pay additional cash
amounts based on the achievement of certain performance measures for up to five years ending after the acquisition dates.</U> The Company measures <U>this</U> contingent consideration at fair value at the acquisition date for acquisitions completed
on or after January&nbsp;1, 2009<STRIKE>. The fair value</STRIKE><STRIKE> of</STRIKE> <U>and records</U> such contingent consideration <U>as a liability on the Company&#146;s Consolidated Balance Sheet on the acquisition date</U>. <U>The fair value
of each contingent consideration liability</U> is remeasured at each reporting period with any change in fair value recognized as income or expense within continuing operations of the Company&#146;s Consolidated Statements of Income. Contingent
consideration liabilities for acquisitions completed prior to January&nbsp;1, 2009 are not included on the Company&#146;s Consolidated Balance Sheet and are recorded to goodwill as incurred. See Note X for more information on the Company&#146;s
business acquisitions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>6. Business Acquisitions, page 64 </U></I></B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2.</I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In your response to the first bullet of comment four you indicate that you value hospital agreements that contain provisions for administrative fees using an
income approach method. Please explain how you value the hospital agreements that do not contain provisions for administrative fees. If you use a method other than an income approach, please explain to us why you use that method and how you apply
it. </I></B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hospital agreements represent the contracts between the acquired physician practice
and the hospital for which the physician practice provides services. Certain hospitals in which we operate require contracts while others do not require contracts. There is no significant economic difference between the operations that have a
contract and those that do not have a contract. In addition, most of our hospital contracts are terminable with 90 days or less notice. If a hospital were to cancel a contract with a physician practice, the physicians in that practice could continue
to practice in the hospital because they are credentialed by the hospital. Therefore, following the cancellation or expiration of a hospital contract, we would continue to generate revenue from our physicians providing services to patients in that
hospital. From time to time we have operated initially in a hospital pursuant to a contract that subsequently expired and was not renewed. The physicians have continued to practice at such hospital, and there has been no significant change in the
patient service revenue generated at that hospital from the time that they are operating with a contract to the time that they are operating without a contract. Unlike the hospital agreements that provide for administrative fees, we do not generate
any revenue beyond that generated by the clinicians rendering services at the hospitals. Accordingly, there is no measureable value associated with or allocated to the hospital agreement other than the avoided cost of reproducing or replacing the
agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use the cost approach method to estimate the value of the agreements
based on the costs to reproduce or replace the hospital agreements. We consider the time and costs associated with the reproduction of the hospital agreements such as the time and resources dedicated to contract negotiation and administration. This
methodology is based on the avoided costs, time and effort that we would incur if we were to go out and create and reproduce such agreements as opposed to acquiring them in business acquisitions. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>3.</I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Also in your response to the first bullet of comment four you indicate that you value physician agreements using a cost approach method. Please explain to us why
you believe that the cost method is appropriate to value your physician agreements when you believe that the benefit of acquiring a practice is in the physicians&#146; established relationships with other physicians and professionals at a hospital
and their reputations in the community. It would appear that each physician&#146;s relationships and reputation are unique to the individuals and that the value of the agreement with that individual is more than just the cost to recruit and replace
a physician that leaves a practice. In your response explain to us why a cost approach is appropriate considering that such methods are generally faulted for not capturing the earnings potential of the related asset. In addition, tell us whether and
how you considered other valuation methods to value your physician agreements and why you did not utilize those methods. Also in your response, please tell us specifically your consideration of using a with-and-without concept to assess the entire
impact on your operations to replace an individual physician which would include not only the cost to replace the individual but also the opportunity cost in terms of lost revenues and profits until the replacement physician can establish
relationships and a reputation commensurate with that of the departing physician. </I></B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
believe that the benefit of acquiring a physician practice is the fact that there is a group of physicians and other professional employees, not any one individual physician, that has established relationships with the other physicians and
professionals at the hospital, as well as the hospital&#146;s management and is known in the community. In accordance with ASC 805-20-55-6, we consider the collective physician group and other professionals within a practice as an assembled
workforce that permits us to continue to operate from the date of acquisition. The physician group practice is not separable from the business as it cannot be sold apart from the business because it truly is the operations underlying the business
and the collective group of physicians cannot easily be replaced at one time without significant economic impact on the business and its relationships. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The fact that one individual physician or other professional does not decide to become an employee of the Company at the time of the acquisition would not diminish the value of the acquired physician
practice. As discussed above, the value of the practice could be diminished if all of the physicians and other professionals did not elect to join the Company. Further, if a majority of the physicians did join the Company, based on our historical
experience of hiring clinicians across the country, we could without difficulty replace an individual physician who elected not to join the Company with another physician. Based on our historical experience, because of the minimal time it would take
to replace a physician in the group and the fact that no significant economic change is expected to occur in the underlying physician group&#146;s operations if one physician leaves either due to death, retirement or for other reasons, we have not
performed a with-and-without assessment. It is important to emphasize that the established relationships are with the collective group practice and not dependent on any individual physician within that physician group practice. Accordingly, because
the assembled workforce does not meet the separability criterion, the value attributable to the collective physician group is subsumed into goodwill. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Further, as a result of the expertise and infrastructure that we have built in becoming a leading health care services company, a significant portion of the profit that we expect to generate from the
practices that we acquire is the result of improvements that are made after the acquisition, including improved contracting with managed care organizations, improved collections, identification of growth initiatives, as well as operating
efficiencies and cost savings. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, we use the cost approach method to estimate the value of
physician agreements based on the costs to reproduce or replace them. We consider the time and costs associated with the reproduction of the physician agreements such as the time and resources dedicated to application processing, credentialing,
provider education programs and administration. This methodology is based on the avoided costs, time and effort that we would incur if we were to create and reproduce such physician agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>9. Accrued Professional Liability, page 66 </U></I></B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>4.</I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We acknowledge your response to comment five. Please tell us how you estimate your professional liability losses in total and those that have been incurred but
not reported. In your response, please tell us whether you use loss triangles that identify all losses expected to be incurred by loss year and track the estimated change in expected losses to be incurred in each subsequent year. If not, please tell
us how your actuarial computation of IBNR reserves captures claims incurred in prior loss years that have not yet been reported if you do not separately estimate losses by loss year. In this regard, please explain how you are able to determine if
all claims incurred in a particular loss year have been reported or whether you consciously adjust the frequency of claims in a given loss year separately from their severity. </I></B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our total accrued professional liability reserves are comprised of loss reserves for reported claims and a loss reserve
for unreported claims (incurred but not reported loss reserve or &#147;IBNR&#148;). Our total loss reserves for reported claims consist of individual case reserves related to each reported claim, limited to our self-insured retention amounts, plus
an additional reserve for adverse deviation associated with known claims. Our IBNR reserve represents our best estimate of the aggregate liability associated with unknown claims at each reporting date. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We perform two separate actuarial studies to estimate our total professional liability reserves: a claims-made study to
estimate our loss reserves for reported claims, including amounts for adverse deviation (&#147;Claims-made Study&#148;) and an IBNR study to estimate our aggregate reserve for unreported claims (&#147;IBNR Study&#148;). Our Claims-made Study uses
multiple actuarial methods, some of which use loss triangles to evaluate loss data, to estimate ultimate expected future losses related to each claims-made policy year. Case reserves and actual paid losses obtained from third-party loss runs are
deducted from ultimate expected future losses to arrive at loss reserves for adverse deviation by claims-made policy year. Therefore, we are able to disclose current and prior year provision as well as current and prior year claim payment data
related to our loss reserves for reported claims as reflected in our Accrued Professional Liability footnote. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our IBNR Study also uses multiple actuarial methods and loss triangles to evaluate loss data and to estimate ultimate
expected future losses. Unlike our Claims-made Study, however, our IBNR Study is prepared on an accident year basis using occurrence-based loss data and the IBNR Study is not tied to individual claims-made policy years with individual claims and
claim payments. The objective of our IBNR Study is to determine how much of our ultimate expected future losses remain unreported at each reporting date. Our IBNR Study accomplishes this by applying emergence patterns and other adjustment factors to
ultimate expected future losses by accident year. The changes in our IBNR by accident year, however, cannot be evaluated in terms of current and prior year provision and payments due to the nature of our estimation process. Instead, the end result
of our IBNR Study is an actuarially-determined aggregate estimate of our IBNR reserve for which changes are not specifically identifiable to current and prior years, and are therefore not conducive to presentation in the current table provided in
our Accrued Professional Liability footnote. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, we disclose our IBNR reserve as an aggregate
liability and, as previously communicated to the Staff, will expand our discussion to identify any material changes in our IBNR reserve associated with the growth of our business by acquisition, changes in actuarial assumptions and/or other relevant
factors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>15. Commitments and Contingencies, page 74 </U></I></B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>5.</I></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We acknowledge your response to comment six. You disclose in the third paragraph on page 75 that the audits, inquiries and investigations by government
authorities and agencies could have a material adverse effect on your business, financial condition, results of operations, cash flows and the trading price of your common stock. </I></B></FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&#149;</I></B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Please provide us proposed revised disclosure to be included in future periodic reports that estimates the possible loss or range of loss or
states that such an estimate cannot be made for your third-party payor audits, inquiries and investigations that are at least reasonably possible but not accrued, either because it is not probable that a loss has been incurred or the amount of loss
cannot be reasonably estimated, as required by ASC 450-20-50-3 and 50-4. If you cannot make an estimate, please disclose that fact. </I></B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to your comment, we will expand our disclosure related to audits, inquiries and investigations within the Commitments and Contingencies footnote in future periodic reports as follows: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the
ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#146;s business, financial condition, results of operations,
cash flows and the trading price of its common stock. <U>The Company has not recorded an accrual for these matters as of December&nbsp;31, 20xx in its Consolidated Financial Statements, as the variables affecting any potential eventual liability
depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </U> </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&#149;</I></B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Please provide us proposed revised disclosure to be included in the revenue recognition section of your Application of Critical Accounting
Policies and Estimates disclosure in future periodic reports that addresses the following: </I></B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="20%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&#149;</I></B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Please revise your disclosure to clarify for all the periods presented whether you have recorded any material adjustments to prior period
contractual allowances for any reason </I></B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="20%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&#149;</I></B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Please revise your discussion of the impact of a one percentage point change in your estimated collection rate on your gross accounts receivable
to specifically indicate whether you believe such one percentage point change to be reasonably likely. If not, please revise your disclosure to cover a reasonably likely change. In addition, please revise your disclosure to highlight the fact that
the impact of your one percentage point change excludes the impact on previously billed and collected receivables that are subject to audit, inquiry or investigation by government authorities and agencies and other third-party payors.
</I></B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:24%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to your comments, we will expand the revenue recognition section of the Application of
Critical Accounting Policies and Estimates disclosure in future periodic reports as follows: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:24%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:24%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize patient service revenue at the time services are provided by our affiliated physicians.
Almost all of our patient service revenue is reimbursed by government-sponsored healthcare programs (principally Medicaid) and third-party insurance payors. Payments for services rendered to our patients are generally less than billed charges. We
monitor our revenue and receivables from these sources and record an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. Accordingly, patient service revenue is presented net of
an estimated provision for contractual adjustments and uncollectibles. Management estimates allowances for contractual adjustments and uncollectibles on accounts receivable based </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:24%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
upon historical experience and other factors, including days sales outstanding (&#147;DSO&#148;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past
adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference
between the physician rates for services performed and the reimbursements by government-sponsored healthcare programs and insurance companies for such services. The evaluation of these historical and other factors involves complex, subjective
judgments. On a routine basis, we compare our cash collections to recorded net patient service revenue and evaluate our historical allowance for contractual adjustments and uncollectibles based upon the ultimate resolution of the accounts receivable
balance. These procedures are completed regularly in order to monitor our process of establishing appropriate reserves for contractual adjustments. <U>We have not recorded any material adjustments to prior period contractual adjustments and
uncollectibles in the years ended December&nbsp;31, 20xx, 20xx or 20xx.</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:24%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">DSO is one of the key factors
that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding
accounts receivable. Any significant change in our DSO results in additional analyses of outstanding accounts receivable and the associated reserves. We calculate our DSO using a three-month rolling average of net patient service revenue. As of
December&nbsp;31, 20xx, our DSO was xx.x days. We had approximately $xxx.x million in gross accounts receivable outstanding at December&nbsp;31, 20xx, and considering this outstanding balance, <U>based on our historical experience,</U> a
<U>reasonably likely change of x% to x%</U><STRIKE>one percentage point change</STRIKE> in our estimated collection rate would result in an impact to net patient service revenue of approximately $x.x million<U> to $x.x million</U>. <U>The impact of
this change does not include adjustments that may be required as a result of audits, inquiries and investigations from government authorities and agencies and other third-party payors that occur in the ordinary course of business. See Note X to our
Consolidated Financial Statements in this Form 10-K for further information.</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:24%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net patient service
revenue, net income and operating cash flows may be materially and adversely affected if actual adjustments and uncollectibles exceed management&#146;s estimated provisions as a result of changes in these factors. <STRIKE>In addition, we are subject
to audits of our billing by government-sponsored healthcare programs and other third-party payors. See Note 15 to our Consolidated Financial Statements in this Form 10-K.</STRIKE> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;&nbsp;*&nbsp;&nbsp;*&nbsp;&nbsp;* </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with our response to the Comment Letter, the Company hereby acknowledges that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is responsible for the adequacy and accuracy of the disclosure in the filing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the
filing; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of
the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you or any other member of the Staff should have any further comments or questions
regarding this response, please feel free to contact the undersigned by phone at 954-384-0175, extension 5083, or alternatively, at the address provided elsewhere in this letter, with a copy to Thomas W. Hawkins, the Company&#146;s general counsel,
at the same address. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Vivian Lopez-Blanco</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vivian Lopez-Blanco</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">cc:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kei Nakada (SEC)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Brunhofer (SEC)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomas W. Hawkins</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g297036corresp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g297036corresp1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`70"J`P$1``(1`0,1`?_$`*$```$%`0$!````````
M```````#!`4&!P@"`0$!``,!`0````````````````$"`P0%$``!`P,"`P0$
M!PL+!0$````!`@,$`!$%$@8A,1-!(A0'46$R%7&!D7+2(Q:A0E)B@C-3<[-5
M%\'1DJ*R8],D5)0(PI,E-3<8$0`"`@$#`P0"`P$``````````1$"`R$Q$D%1
M!&%Q$Q0B,H&10J'_V@`,`P$``A$#$0`_`.J:`*`*`*`*`*`*`*`^+4$(4L\0
MD$V'JH"L[9W<_EI[L9YA+:=)<94F_($"RK_#SK.F27!:U8+/6A4:Y5^1'QLI
M^.C6^VTI3:>=U`<.%0]@BE["DYJ1EWW'G''(Q02^I9)3U"1IMV7_`)*QQ-MZ
MEK%^K<J%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`%`5O=&ZUXMU,2*VER4I(4LK
MOI2D\!P'.L[Y.)95DJ^#W5X"8I]R(Q9\_7K:"DK2B]^[Q4FU^-N%8URP]46X
MZ&E-N(<;2X@ZD+`4E0Y$$7!KJ,RF;UW)D(LY./AN]!(0%NN)X*)5>PU6[H%J
MPS7:T1:M2GQ\SFDK^HDO:[W[JE$W^`5DKLM!H&SMS.Y1I4:9;QK2=6H<-:+V
MN1V*!YUT8[S[E76"RUH5"@"@"@"@"@"@"@"@"@"@"@"@"@/+KK3+:G'5AMM(
MNI:C8`>LFC8/C+S3S:765I<:5Q2M)!!^`B@*=+QT.=(W#DI9);C!3,<W("5M
M-"ZN'H/"L71.6RTE0Q;+#\QN.\JR'26@H_>K6+(4?RK5CC:G7J7LM)-!VKD>
MCCW,=/4&9>-!#J5\/JAQ2L>D`<+UTT?1]#-HKDQ*Y[F5S[[93"0VIJ)KX=0K
M`;20/4*S:WL6]"`P,T0<M'E*%VVEA3@_%Y&WQ&L:.&2RZ>[DP][PI,0#PL]M
MQSN^R#H.JWJ/!5=$?G/<K.A<*U*A0!0!0!0!0!0!0!0!0!0!0!0!0$%N^=B6
M\8Y#G.J0N2/JTMC4NZ3<*L;"P([:ID:B&2D5_:F0G>#.*Q;:BXM747+=MH:0
MJR20D$\>[PN>=98[:0BUD>]W96)$CC"0AW$G7,6.943JL3]\HJ[RJ9K0H0JI
MU*:I!ZB5ZBI0MI%C?ARX\:YDX+&P)BPY\9AZ2PATJ0E0*T@GB+]M>B9%<\PI
M/3@Q(38%G5E10.'!`LD?*JL<VT=RU40.7V9,AX5N>MP%Q-C(8`]@*``XWXD<
MCPK)X84DID]@<DVW@L9D)*"MJ%U(SSH!*FPJP"[#LL`#6U+?BF0$;>#JLT^'
MGFQC$72RE`"E+5>R-!'>45>BI5G/H&BVMJ4I"5*24$@$I/,7[#:M"IZH`H`H
M`H`H`H`H`H`H`H`H`H"F[TCPX\=YUS2]E)JTI8OS;:01P0.S^4FL<L1J6J,?
M+U;D?+R8KJ2VMUJY00004*X<#RX*-5Q.'!-MB9W^TI>)82V.\J2A-P./>2H5
MIE4HBHEG\6W'E[>Z*``T\B.>RX%B/[)J+K5!,ME:E2KY.,J?O2&P>+$1@/NC
MF+ZSI_K`5FU-EZ$]"PSXJ9<%^*KV7FU(_I"U7:(*UL\F'M>:I\72RX\5)5^*
MD7!^,5GC_4O=RR!V2A#6<9\8UI#J%&(M8[I7?FFX]`(%9XE#UZDV9I5=)F%`
M%`%`%`%`%`1.0W;M?'2E1)^6B1)2`"IAYY"%@*%P2E1!XU,,H\E4X;%\5N#!
MY8N#%SX\XLVZOAW$N:=5[:M)-KVHTT36Z>S']06(B?N_:V/E*B3LM$BRD`%;
M#KR$+3J%Q=)-Q<5,,J[U6[$/M_L?]_0/]PU]*G%D?+7NCX=_;(M_[^`/7XAK
M^>G%CY:]T1C&<\MVYWCG<_#E2[W2Z_*:7I^:+@"J_'K(^:O=`K=.QU;B1D_?
MN/2E$<M$^):NI2E?.[$BG!S)/S5B)1(O9K;.=\.Q!RL.4XU(:>Z;;[:E'0J_
M!(-ZEU862KV9+SXB'U1G%D)3%=#Y)_%2H?\`5406(H>8&QSQ]_0/]PW]*K<6
M9_+7NB3B1(_BW\BVL.F6AL(6FQ3TTCNZ2.8.J]5@TD,IF<3BF4O9.8S"96K0
MAQ]:6TE5KV!41QL*LD1:R6Y#XW*[1R+4K$8[*Q93LWKN%EAY"UV<N5$)2;\+
MU#KH17(F]&>MP939V+CPX6X)D:,=-XH>5H5]6`"I!'$6N**DBV2M=V.,%NW:
MV7=,/$91B<^RC6IMMS6L(!`U&_$\3SJ75HBN2MMF/LIFL1B6D/9.8S":<5H0
MX^M+:2JU[`J(XT2;)M9+<81][[.D/ML,9N$Z\ZH(;;3(;*E*4;```\233BR%
MDK,2B;J"Y"RMZ[0BR7(TG-0F9#*BAUE;[:5)4.84">!J>+*/)5=4+1=T[;EM
M%Z+DXKS(44%Q#J%)U)3J4+@VX)XFD,E734R.O>V+_P!6S^=\/^<3^>_1\_:]
M51#)E'-/GN!_$F;^HC?LZWQ['E^7^Y!^7V\)&T]S1\FBZHBOJI[*?OV%'O</
MPD^TFK.LJ#/#DX6DZ:W5O;%X+:;NX0XE]E;:50$@\'W'1=I*3^-S/JK"M9<'
MJY,JK7D<DY&?+R4^1D)KA>ERG%.ON'M4HW/Q>BN@\>UFW+%\+@,OG)9AXF(N
M9*2@N%INUP@$`GB1VD5#9-:.SA$[_";S%_<+_P`K?TJCFC3ZU^Q"YW;.=P+S
M3.8A+A.OI*VD.:;J2DV)&DGMJ4Y,[XW7<\X?;N<S2W48B`]/6R`IY+"=12%7
M`)^&U2W`K1VV1\RNW\YAW$)RF/D05J_-E]M2+G\51%C\1HG(M1UW4%]\MO-S
M+8E]&'S4E<O#21T$.O*U.1E+&E*@L\2W^$#RYBJVJG[G1@\AIP]C.)<*3"E/
M0Y39:DQEJ:>;/-*T&Q'"KLYG6'#-G\B_,OIJ;VEEW>XHVQ$A9Y'_`$ZB?ZGR
M>BLLE>J.WQ<_^7_!-_\`(\`[2QQMQ$]/[)=1C+>;LC//(0#^(L<^B+(_LBK9
M-C#Q/W_@B_-?='VCWK-D-+UPHA\'#MR*&B0I0^<O4:FJA%,]^5FR/V#N9>VM
MVX_*ZBF.ASIS`.UASNN?(.]\(J6I17#?C9,ZIW/M[&[GV_)Q<NRX\MN[;J;$
MH5S;<0?2D\:YZN')ZUZ*RAG(V=PF1P&:DXN<DM3(;EM2>%[<4.(/H4+*372F
M>/>CJX9M3'GBTGRT,I;B3NEO_(AH\U.Z>$FWX.GO'\;A6?Q:^AW+ROPG_1BV
M$PV3W%G&,;$!>G3G3=Q?'F=2W%GT`74:T;2]CAK5V<=6=8X#9F'PVW8N#81J
MCL(4EQ?(N+<20XM5NU5S7.[-L]BF-54'O[&X#]"OT_G7.?X7/VO73DR/BKV.
M>O/?_P"DS?U$;]G6N/8\_P`O]RF+Q$]&':S'3)@.OKBAX<DO(2E>E7HNE5Q\
M=7DY^+B>@I,W#EIF'@8>3(*\?C2XJ(R>22Z;JN>VW9Z*=9)=VTET1XR6%R&-
MCP'IC?2&28\5&2?:+164)41V:M-QZJ$.K0_V;O')[2RRLICFF79"VE,%+X4I
M&E1"CP2I!OW?34-)HMCR.CE%W_\`T9O;_18[_MO?XM4^-'1]R_H0GF7N:?N:
M!MK,ST-MRI$>6E:&0I*`&Y.@6"BH\AZ:M6L2C/-D=TFRV?\`&K_VN=_41_[:
MZID-O"W9MF=P>-SF)D8O(M!Z+)04J!%RDGDI)[%)/$&LZMIRCNO564,XRE1R
MQ(?C*.HLN+:4?3H44W^Y72>*U#@G=[#7*Q<]7YV?BH<A\\R7`@M*4?6H-`U%
M47RO9^B(G(8_(8J<8TMM4>4V$.)'(V6`MM:5#L((((JWL4::<,O6[_,8;J\N
M\?"GK'OV!,0)'9UFNDL!X>OL7Z_AJBK#T-\F;G53NBI[5W"[@)LN<Q<27(;\
M:,H?>N/@("OR1<U,298[\9?H?=E[><W#NC&XA`)1(='7(^]91WW3_1!I9]1B
MIRLD.?,3;/V;WAD<6A&F*%]6$.)'0=[R!<\]/L_%2KG4G+3C9HW[R3W3[\V4
MPP\O5-Q)$1^_,H2+LJ^-'#X0:QR*&>CXV3E7U1#^?FS(<_`_:1LH9GXP!+JE
M'3UF%*MH]:DJ5=/QBK8GT*>7C3KRZHYVK5GFG1/D%LV'`P'VC6M#\_*`I;4@
MWZ+*56Z?SE*3=7Q"L<CU@]+Q,<5Y=6:O69UA0'+_`)[_`/TF;^HC?LZWQ['E
M^7^Y=O)S;D#<?E?E\1.3=F3-<"5CVFUAILH<3ZTJXU6[AFOC45L;3[E,V1Y4
M9/(;[?PV79*(6'<"\FNW=<3>[2$'T/#C\V]7M;23+%X[=X>R)/\`Y%H0WNS&
M(0D)0C'I2E*18`!U8``%5Q[$^9^R]BL>5T+:,S<JVMU*91C!&6I)D.EE'5"D
MZ>\%)XVO5K3&AG@57;\MC6OLU_Q[_3X[_>K_`,2L^5CL^+#Z?V9SYPG:34G"
MP=K/L.XV)'?&B.[UDH6X[K(*B5'CSYUI2=V<OD<=%78>^1.Z=O[?R.7=S,YN
M"W(992RIV]E%*E%0%@>5ZC)62WBY%5N6:!O+SUVM`Q;S>!D#)Y5Q!3'+:5!E
MM1X:UK4`#IYV%[U2N.=SIR>55+35G.L:++GS&HT=)>ERG`VTGM4XX;#Y2:V9
MYB39);RF19&54S$6'(>.CM8^.Z.2TQF]"ECU+<U*'J-$B^2R;TZ:&[[^\N$[
MJV7C9L!`&=@0V3'/+K-],%3*C]U)]/PUC2T,]#+AYT4;G.*T+0M2%I*%H)2M
M"A8A0-B"#V@UL>8?*`D,'N/+X":J;B97A):D%HNA*%*T*()`UA5KV%(+4NZN
M4>\_NC-[ADM2<Q+,R0RCI-N*2A)"+E6GN!-^)H+Y'9RRW^1^Z/<N]6HCJ],/
M,)\*Y<\`[>[*OZ7=_*JMZRC;Q<G&WN/O/#S!]^9?W%CW+XK&+/66D\'I(X$^
MM+?(>NY]%12L*2_E99?%;(H1VUF1MU.XC'/NE4@Q0_\`W@%[V_!OW=7IX5II
MMU.;@^/+H7KR1\P?<&9]RY!S3B,FL!"U'NLR3P2KCR2OV5>NQK.ZE>IT>+FX
MN'LSI.L#TPH#G_S>V!O+,[ZE9#%XIV5#<982AY!18E"+*'%0/`UK2R2//\C#
M:UY2+YY'[=S>!VM*B9>(N')7,6ZAM9224%M`![I/:#5;N6;^+1UJT^YH26VT
MK4L)`6NVI0`!-A87/;5#I,4\\=D[KSVYH4K#XUR9':AAI;B"@`+ZJU6[RAV&
MM:621P^3AM:TI=#.?X3>8W[B?^5OZ57YHY_K7[!_";S&_<3_`,K?TJ<T/K7[
M!_";S&_<3_RM_2IS0^M?L'\)O,;]Q/\`RM_2HK)CZU^P_P`;Y(^8LUQ(7CT0
MFSS=DNH2!^2@K7]RG-(E>+=FN["\G,9M5MR?)<&1SA;6EM[3I;9U)((:2;\3
MRU'C\%96R2=F+QE37=F(J\I?,?ID>XG[Z;>TWZ/G5KS1Q?6R=CJG"LNL8>"R
MZG0ZW':0X@\PI*`"/EKG9ZE5HC(_./RCG9&>G/;:B]:3)5IR,-!2DJ5V/IN0
M+GDOY?36V.ZV9R>3X[;Y5,T/E-YCWM[B?O\`.;^E5N2.;ZV3L=$[4\O]OXC;
MN/Q\G'19$IAE(DON,MK4MU7><.I0)]H\*QM9MGHX\2K5*!?/[#VUE,+-QZ,;
M%CN265MMOML-H6A9'<6%)2"-*K&BLTR;8JM1!SC_``G\R6W.[A']:#P6A3?,
M'FDZODK;FCS?K9.PZQ/DWOR;DXT:7C'845UP)D2W"@AM'-2K!1)-N7KH[K<F
MOC7;U1T<YM+!KVO]F2P!B>AX8-=H3;@J_P"'?O7]/&L.6LGI?&N/'H<WY3R:
MW_$GR(T?%N3([3BD,RFU("7$`]U8!4"+BM^:/-?C7G1&]^6,O=3FW&X>YX+L
M7(P;,I>=*3UV@.XNZ2>\!P5\O;65XG0]##RXQ;<MU4-2NKW*\QF9T.2@)BME
M+<:1R`=+06$+^=V5GSUU)@1D;FGHPV.>90VYD939?<0>">FV-3AY]O(4=W")
M@6FY+,+>@.P)+`AY)02R%ME2DW;*[DA0ORJ+6>D=24D>%Y[*,R),*S3LL2&(
ML=9!2C4XUK6M5C>PXV%3R>Q$!-S&9Q?78EK9?=5&<D1'T(*!J:MJ2M-SZ>!O
M1V:"@4B;D>DR<;'*`S(=<<:GL*'>2I#16"G\57,&G,B#[C]QNR<VY&6E`@O%
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MMW<TL,P=,^(E+RWD/S`A9:'3"2GNJ*2%'55'?8F!6+N'*2T,Q8_1,M]YUMJ9
MI5T5,LI!+J4DW/.UKU*LV1!ZDYS+P5NPY1:<E-KCJ;>0DA*VGG>FJZ;FRA\-
M'9H0*[BSDW'OO(8T:40S(25)OWP\E'I'"RJ6O`2%,)F),G(.PW'V)K:&@[XF
M,"E*5%5M"N*A?M%35O9AD[5R"N2O<=L]XPK+6MOQ06$V"NDG1TK&]^7/MK/\
M=21AC!M8%GQJBH>%9\)XT-A/2NKV+$C5J]JH7'J2QSCQB^GC>BI_P_CGO`:D
MHT^RO@.-^GST]M3IH#Y/&%Z^5ZQD>(\3'T],)UB1TAT^A8\3;TU#C4""Q"Z<
M\914TSO"*[TA+07T+C5T0A11S]JYIW`XRHPYRL+IJ=&5\,[H+`05]/HFVO40
M-5KZ?YJ.)]1K`W;&T?"X[P!`F]1GH%D(,G5_>`D>O73\=`Y%L"E[J,^#7/./
MZKE@I$8,^VK5<A74MJO2GI(9(K&+]^S?$$Z^@QU@Z$]&W45T[$F]]7IJVG(@
MAY*87BU>&7,$SWA(T=%+)5U>D-=M:@-.GE>HT)/<E,GJPNJYD?>'UW1(1&ZF
MBR==^]HMZ.VH>ZW`I"&%M"T&1U_'*Z_6`ZID=)5^O<\!IY6J5!`C$#-D&"K)
M^Z>J>@EI+?2U:C;2;]7IZO5:H]I@D3`VC[G2$J/C]0LH!OQW7ZGHO;5J]=J?
MC`U'&/2_X^1X)>0Z/C%^)`1&Z75U#7<E6O31;Z2!]GQ&.1C=$R4Y;IJZ1B!!
M5T;B_4#A"-.KT]M6M_TA#&`,-XN%K,CQ`?E]7Q(;XN]-/5ZECI'"UM-4K$DL
M22,3X%KPJIG&2OW/TDIZ@_2='4>+7S[4<0H![2,.(N3&0,LS_JO$%X($CVOJ
M>B$$HMKY6//G4N-9`D^(7ALB,FN<9?AT:E/I9#G0Z@MT@A6CV_:N:AQK(+;#
5\'TAX71H[>GIM?UZ:U4="HO4@__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
